Pan-tumor Activity of Olomorasib (LY3537982), a Second-Generation KRAS G12C Inhibitor (g12ci), in Patients with KRAS G12C-mutant Advanced Solid Tumors.Rebecca Suk Heist,Takafumi Koyama,Yonina R. Murciano-Goroff,Antoine Hollebecque,Philippe Alexandre Cassier,Ji-Youn Han,Diego Tosi,Adrian G. Sacher,Timothy F. Burns, Alexander I. Spira,Carlos A. Gomez-Roca,Toshio Shimizu,Natraj Reddy Ammakkanavar,Joshua K. Sabari,Misako Nagasaka, Aaron Alan Fink, Aaron Chen,Melinda D. Willard,Geoffrey R. Oxnard,Yasutoshi KubokiJOURNAL OF CLINICAL ONCOLOGY（2024）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
